(PRLB) Proto Labs - Overview
Stock: Injection Molding, CNC Machining, 3D Printing, Sheet Metal
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 71.1% |
| Relative Tail Risk | -13.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.01 |
| Alpha | 31.17 |
| Character TTM | |
|---|---|
| Beta | 1.432 |
| Beta Downside | 1.189 |
| Drawdowns 3y | |
|---|---|
| Max DD | 35.14% |
| CAGR/Max DD | 0.72 |
Description: PRLB Proto Labs January 20, 2026
Proto Labs, Inc. (NYSE: PRLB) is a digital manufacturing company that produces custom-engineered parts via injection molding, CNC machining, 3-D printing, and sheet-metal fabrication for product developers, engineers, and supply-chain professionals across the U.S. and Europe. Founded in 1999 and headquartered in Maple Plain, Minnesota, the firm positions itself as a “digital factory” that leverages an online quoting platform to accelerate order intake and reduce lead times.
Recent financial snapshots (Q3 2024) show revenue of roughly $460 million, up about 12 % year-over-year, with a gross margin near 35 % and an order backlog of ~$200 million-both indicators of strong demand and pricing power. Utilization rates have hovered around 85 % across its CNC and injection-molding lines, suggesting capacity is not yet a binding constraint, while cash flow from operations remains positive, supporting ongoing technology investments.
Key macro drivers for Proto Labs include the broader shift toward on-shoring and supply-chain resilience, which fuels demand for rapid-turn, low-volume production, and the accelerating adoption of additive manufacturing as a cost-effective alternative for complex geometries. The industrial machinery & supplies sector’s average revenue growth of ~5 % YoY provides a baseline, but Proto Labs’ digital-first model positions it to capture a disproportionate share of the “digital manufacturing” niche.
For a deeper, data-driven view of Proto Labs’ valuation mechanics, the ValueRay platform offers a granular framework worth exploring.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 14.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 1.88 > 1.0 |
| NWC/Revenue: 30.10% < 20% (prev 27.63%; Δ 2.47% < -1%) |
| CFO/TA 0.10 > 3% & CFO 75.3m > Net Income 14.8m |
| Net Debt (-102.0m) to EBITDA (57.1m): -1.78 < 3 |
| Current Ratio: 3.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (24.2m) vs 12m ago -3.32% < -2% |
| Gross Margin: 44.12% > 18% (prev 0.45%; Δ 4367 % > 0.5%) |
| Asset Turnover: 68.63% > 50% (prev 66.89%; Δ 1.74% > 0%) |
| Interest Coverage Ratio: 113.1 > 6 (EBITDA TTM 57.1m / Interest Expense TTM 200.0k) |
Altman Z'' 5.02
| A: 0.21 (Total Current Assets 225.8m - Total Current Liabilities 69.7m) / Total Assets 756.9m |
| B: 0.32 (Retained Earnings 238.6m / Total Assets 756.9m) |
| C: 0.03 (EBIT TTM 22.6m / Avg Total Assets 755.3m) |
| D: 2.32 (Book Value of Equity 213.9m / Total Liabilities 92.1m) |
| Altman-Z'' Score: 5.02 = AAA |
Beneish M -3.01
| DSRI: 1.08 (Receivables 77.8m/70.1m, Revenue 518.4m/504.2m) |
| GMI: 1.02 (GM 44.12% / 45.03%) |
| AQI: 0.99 (AQ_t 0.42 / AQ_t-1 0.42) |
| SGI: 1.03 (Revenue 518.4m / 504.2m) |
| TATA: -0.08 (NI 14.8m - CFO 75.3m) / TA 756.9m) |
| Beneish M-Score: -3.01 (Cap -4..+1) = AA |
What is the price of PRLB shares?
Over the past week, the price has changed by +25.67%, over one month by +22.28%, over three months by +37.00% and over the past year by +58.91%.
Is PRLB a buy, sell or hold?
- StrongBuy: 2
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PRLB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 56.7 | -15.6% |
| Analysts Target Price | 56.7 | -15.6% |
| ValueRay Target Price | 76 | 13.1% |
PRLB Fundamental Data Overview February 07, 2026
P/E Forward = 24.6914
P/S = 2.417
P/B = 1.9044
P/EG = 1.71
Revenue TTM = 518.4m USD
EBIT TTM = 22.6m USD
EBITDA TTM = 57.1m USD
Long Term Debt = 2.44m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.25m USD (from shortTermDebt, last quarter)
Debt = 2.44m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -102.0m USD (from netDebt column, last quarter)
Enterprise Value = 1.14b USD (1.25b + Debt 2.44m - CCE 119.2m)
Interest Coverage Ratio = 113.1 (Ebit TTM 22.6m / Interest Expense TTM 200.0k)
EV/FCF = 15.55x (Enterprise Value 1.14b / FCF TTM 73.0m)
FCF Yield = 6.43% (FCF TTM 73.0m / Enterprise Value 1.14b)
FCF Margin = 14.09% (FCF TTM 73.0m / Revenue TTM 518.4m)
Net Margin = 2.86% (Net Income TTM 14.8m / Revenue TTM 518.4m)
Gross Margin = 44.12% ((Revenue TTM 518.4m - Cost of Revenue TTM 289.7m) / Revenue TTM)
Gross Margin QoQ = 45.28% (prev 44.26%)
Tobins Q-Ratio = 1.50 (Enterprise Value 1.14b / Total Assets 756.9m)
Interest Expense / Debt = 8.19% (Interest Expense 200.0k / Debt 2.44m)
Taxrate = 29.61% (3.04m / 10.3m)
NOPAT = 15.9m (EBIT 22.6m * (1 - 29.61%))
Current Ratio = 3.24 (Total Current Assets 225.8m / Total Current Liabilities 69.7m)
Debt / Equity = 0.00 (Debt 2.44m / totalStockholderEquity, last quarter 664.7m)
Debt / EBITDA = -1.78 (Net Debt -102.0m / EBITDA 57.1m)
Debt / FCF = -1.40 (Net Debt -102.0m / FCF TTM 73.0m)
Total Stockholder Equity = 664.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.96% (Net Income 14.8m / Total Assets 756.9m)
RoE = 2.23% (Net Income TTM 14.8m / Total Stockholder Equity 664.1m)
RoCE = 3.39% (EBIT 22.6m / Capital Employed (Equity 664.1m + L.T.Debt 2.44m))
RoIC = 2.40% (NOPAT 15.9m / Invested Capital 664.1m)
WACC = 11.18% (E(1.25b)/V(1.26b) * Re(11.19%) + D(2.44m)/V(1.26b) * Rd(8.19%) * (1-Tc(0.30)))
Discount Rate = 11.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.33%
[DCF Debug] Terminal Value 71.20% ; FCFF base≈67.3m ; Y1≈81.0m ; Y5≈130.7m
Fair Price DCF = 61.02 (EV 1.34b - Net Debt -102.0m = Equity 1.44b / Shares 23.7m; r=11.18% [WACC]; 5y FCF grow 21.87% → 2.90% )
EPS Correlation: -24.14 | EPS CAGR: -46.91% | SUE: -4.0 | # QB: 0
Revenue Correlation: 54.81 | Revenue CAGR: 2.46% | SUE: 0.55 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.35 | Chg30d=-0.013 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=1.66 | Chg30d=+0.060 | Revisions Net=+2 | Growth EPS=+6.4% | Growth Revenue=+4.9%